An FDA advisory panel voted to endorse Galleri, a blood test by Grail for screening multiple cancer types, determining that benefits outweigh risks. The panel voted unanimously on safety and by majority on effectiveness and overall benefit-risk profile. The FDA is not required to follow the panel's recommendation but typically does.